Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease.
Fatty liver
Fibroscan
Imaging
Metabolic associated fatty liver disease
NAFLD
Journal
Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
16
05
2020
revised:
19
08
2020
accepted:
04
09
2020
pubmed:
12
9
2020
medline:
29
12
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and represent a common finding in highly prevalent metabolic disorders (i.e. type 2 diabetes, metabolic syndrome, obesity). Non-alcoholic steatohepatitis (NASH) requires liver biopsy for grading and staging the liver damage by the assessment of steatosis, inflammation and fibrosis. In parallel with the development of numerous 'liquid' biomarkers and algorithms that combine anthropometric and laboratory parameters, innovative hepatic imaging techniques have increasingly been developed to attempt to overcome the need for biopsy, both in diagnosis and staging of NAFLD, and in possible use in the follow-up of the disease. In this review, we focused on the different imaging techniques trying to highlight the strengths and disadvantages of different approaches, particularly for ultrasound techniques, in stratifying liver injury and fibrosis in patients with NAFLD / NASH.
Identifiants
pubmed: 32916154
pii: S0026-0495(20)30219-5
doi: 10.1016/j.metabol.2020.154355
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
154355Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no potential conflicts of interest to disclose.